文献速递糖尿病甲状腺疾病

全年龄段微量毛细血管血筛查1型糖尿病与乳糜泻自身抗体的可行性与表现:UNISCREEN人群研究

Feasibility and performance of minimal-volume capillary blood screening for type 1 diabetes and coeliac disease autoantibodies across all age groups: the UNISCREEN population study.
PubMed 文献 · Diabetologia · 2026-02-10

UNISCREEN研究在意大利北部Cantalupo筛查1532名1-100岁居民,采用指尖毛细血管血结合新型抗体检测。无已知糖尿病者胰岛自身抗体阳性率2.3%,乳糜泻自身抗体新检出率3.2%,毛细血管与静脉样本一致性高,提示全人群微创筛查可行。

要点

  • 毛细血管血微量采样结合LIPS技术可全年龄段筛查胰岛和乳糜泻自身抗体。
  • 无已知糖尿病者胰岛自身抗体阳性率2.3%,乳糜泻自身抗体新检出率3.2%。
  • 乳糜泻自身抗体阳性率随年龄显著下降,胰岛自身抗体年龄分布较稳定。

核心结论

  • 采用微创毛细血管采样和先进免疫分析技术,全年龄段人群自身免疫筛查可行。
  • 临床未受影响个体中自身免疫患病率较高,为早期发现和干预提供机会。

研究设计与样本

  • UNISCREEN人群研究于2023年4月至10月在意大利米兰Cantalupo筛查1532名1-100岁居民,占符合条件人群50.1%。
  • 所有参与者采集指尖毛细血管血,20名自身抗体阳性者提供静脉血确认。
  • 胰岛自身抗体筛查采用新型固相捕获LIPS 3-screen assay,仅需1 μl血清同时检测GADA、IA-2A和ZnT8A,另设单独IAA assay。
  • 乳糜泻筛查采用组织转谷氨酰胺酶IgA(TGA-IgA)LIPS assay。

主要发现

  • 1454名无已知糖尿病者中胰岛自身抗体患病率2.3%(95%CI 1.6, 3.2),其中70.6%为单一抗体,29.4%为多种抗体。
  • 73名2型糖尿病患者中胰岛自身抗体阳性率9.6%(95%CI 3.9, 18.8)。
  • TGA-IgA总体患病率3.5%(95%CI 2.7, 4.6),无已知乳糜泻者中新检出阳性率3.2%(95%CI 2.3, 4.2)。
  • 毛细血管与静脉样本一致性高(各抗体85-95%),随抗体水平从最低三分位至最高三分位由66.7%升至100%。
  • 静脉LIPS与桥接ELISA一致性从GADA的50%至其他抗体的90%,低亲和力GADA部分解释差异。

临床怎么用

  • 全年龄段人群可采用指尖毛细血管血微量采样结合LIPS技术筛查1型糖尿病和乳糜泻自身抗体。
  • 临床未受影响个体中检出自身抗体阳性者需进一步静脉血确认并评估。
  • 成人无糖尿病者检出多种胰岛自身抗体及年龄相关抗体水平差异需纵向随访以了解自然史和进展风险。

局限性

  • 仅筛查单一意大利市镇居民,代表性有限。
  • 静脉LIPS与桥接ELISA一致性有限,GADA仅50%,低亲和力GADA可致差异。
  • 需纵向随访以理解老年人群自身抗体自然史和进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The UNISCREEN study investigated the feasibility of minimally invasive capillary blood sampling combined with novel antibody tests for population-wide screening of type 1 diabetes and coeliac disease autoantibodies across all age groups, with secondary objectives to evaluate the prevalence and age-related distribution of these autoantibodies in a general Northern Italian population. METHODS: Between April and October 2023, we screened 1532 residents (50.1% of eligible population) of Cantalupo, Milan, aged 1-100 years. Capillary blood samples were collected by fingerprick from all participants. A subset of 20 autoantibody-positive individuals provided confirmatory venous samples. Islet autoantibody screening employed a novel solid-phase capture luciferase immunoprecipitation system (LIPS) 3-screen assay requiring only 1 μl of serum for simultaneous detection of GADA, IA-2A and ZnT8A, plus a separate IAA assay. Positive samples underwent confirmatory testing with individual LIPS assays using truncated GADA to improve specificity. Coeliac disease screening used a tissue transglutaminase IgA (TGA-IgA) LIPS assay. Capillary-venous sample concordance and assay format comparisons validated the methodology. RESULTS: Among 1454 individuals without known diabetes, islet autoantibody prevalence was 2.3% (95% CI 1.6, 3.2), with 70.6% having single autoantibodies and 29.4% having multiple autoantibodies. Among 73 individuals with type 2 diabetes, 9.6% (95% CI 3.9, 18.8) were islet autoantibody-positive. TGA-IgA prevalence was 3.5% (95% CI 2.7, 4.6) overall, with 3.2% (95% CI 2.3, 4.2) newly identified positivity among those without known coeliac disease. Capillary-venous sample concordance was high (85-95% across autoantibodies), increasing with antibody level from 66.7% to 100% across terciles. Venous LIPS to bridge-ELISA concordance ranged from 50% for GADA to 90% for other autoantibodies, with low-affinity GADA partially accounting for discrepancies. Islet autoantibody-positive individuals >15 years (measured by 3-screen solid-phase capture LIPS) had significantly higher median antibody levels than those ≤15 years (53.5 vs 19.3 arbitrary units, p=0.006). Coeliac disease autoantibody prevalence declined markedly with age from 9.1% (≤15 years) to 0.6% (>75 years) (p<0.001), contrasting with the more stable age distribution of islet autoantibodies. CONCLUSIONS/INTERPRETATION: Population-wide autoimmunity screening across all age groups is feasible using minimally invasive capillary sampling and advanced immunoassay technology. The substantial prevalence of autoimmunity in clinically unaffected individuals (2.3% for islet autoantibodies, 3.2% for coeliac disease autoantibodies) suggests significant opportunities for earlier detection and intervention. Age-related differences in antibody levels and the detection of multiple autoantibodies in adults without diabetes warrant longitudinal follow-up to understand natural history and progression risk in older populations.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Marzinotto I, Bazzigaluppi E, Brigatti C, et al. Feasibility and performance of minimal-volume capillary blood screening for type 1 diabetes and coeliac disease autoantibodies across all age groups: the UNISCREEN population study. Diabetologia. 2026. PMID: 41665666. doi:10.1007/s00125-026-06680-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。